Pateclizumab - Misplaced Pages

Monoclonal antibody Pharmaceutical compound

Pateclizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	lymphotoxin alpha
Clinical data
Other names	MLTA3698A
ATC code	none
Identifiers
CAS Number	1202526-59-7
ChemSpider	none
UNII	QOK1YYH7J2
KEGG	D10187
Chemical and physical data
Formula	C₆₄₃₆H₉₉₁₀N₁₇₁₀O₂₀₀₄S₄₄
Molar mass	144716.68 g·mol
(what is this?) (verify)

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.

This drug was developed by Genentech/Roche.

References

World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014). "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)". Arthritis Res. Ther. 16 (5): 467. doi:10.1186/s13075-014-0467-3. PMC 4243296. PMID 25359150.
Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012). "Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial". Arthritis Res. Ther. 14 (1): R6. doi:10.1186/ar3554. PMC 3392792. PMID 22225620.
Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol. 63: 82–95. doi:10.1016/j.reprotox.2016.05.014. PMID 27211603. S2CID 41454952.
Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res. 67 (6): 495–501. doi:10.1007/s00011-018-1139-6. PMID 29541795. S2CID 3910200.

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Chemokine receptor modulators

CCR1	Agonists: CCL4 (MIP-1β) CCL5 (RANTES) CCL6 CCL9 (CCL10) CCL14 CCL15 CCL16 CCL23
CCR2	Agonists: CCL2 CCL8 CCL12 CCL16 NAMs: Cenicriviroc (TAK-652, TBR-652)
CCR3	Agonists: CCL5 (RANTES) CCL7 CCL11 CCL13 CCL15 CCL18 CCL24 CCL26 CCL28
CCR4	Agonists: CCL3 (MIP-1α) CCL5 (RANTES) CCL17 CCL22 Antibodies: Mogamulizumab (against CCR4)
CCR5	Agonists: CCL3 (MIP-1α) CCL4 (MIP-1β) CCL5 (RANTES) CCL8 CCL11 CCL13 CCL14 CCL16 NAMs: Aplaviroc Cenicriviroc (TAK-652, TBR-652) INCB009471 Maraviroc Vicriviroc Antibodies: PRO-140
CCR6	Agonists: CCL20
CCR7	Agonists: CCL19 CCL21
CCR8	Agonists: CCL1 CCL16
CCR9	Agonists: CCL25
CCR10	Agonists: CCL27 CCL28
CCR11	Agonists: CCL19 CCL21 CCL25
Ungrouped	Antibodies: Bertilimumab (against CCL11) Carlumab (against CCL2)

CXC

CXCR1 (IL-8Rα)	Agonists: CXCL6 Emoctakin Interleukin-8 (CXCL8, GCP-1) Antagonists: Navarixin NAMs: Ladarixin Reparixin (repertaxin)
CXCR2 (IL-8Rβ)	Agonists: CXCL1 (MGSA) CXCL2 CXCL3 CXCL5 CXCL6 CXCL7 Emoctakin Garnocestim Interleukin-8 (CXCL8, GCP-1) Antagonists: Danirixin Elubrixin Navarixin NAMs: Ladarixin Reparixin (repertaxin)
CXCR3	Agonists: CXCL4 (PF4) CXCL9 (MIG) CXCL10 (IP-10) CXCL11 (I-TAC) Iroplact Antibodies: Eldelumab (against CXCL10)
CXCR4	Agonists: MIF SDF-1 (CXCL12) Ubiquitin Antagonists: Mavorixafor Plerixafor (AMD3100) Antibodies: Ulocuplumab (against CXCR4)
CXCR5	Agonists: CXCL13
CXCR6	Agonists: CXCL16
CXCR7	Agonists: Conolidine CXCL11 (I-TAC) CCX771 LIH383 RTI-5152-12 SDF-1 (CXCL12) VUF15485 PAMs: Plerixafor (AMD3100)

C (XC)

XCR1	Agonists: Lymphotactin-α (XCL1) Lymphotactin-β (XCL2) Antibodies: Pateclizumab

CX3C

CX3CR1	Agonists: Fractalkine (CX3CL1)

Others

CCBP2	Agonists: CC (β) chemokines
CMKLR1	Agonists: Chemerin Resolvin E1

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: